Andreas Kuznik
Overview
Explore the profile of Andreas Kuznik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1010
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lanitis T, Khan A, Proskorovsky I, Houisse I, Kuznik A, Kamat S, et al.
Contemp Clin Trials Commun
. 2024 Dec;
42:101390.
PMID: 39634516
Background: Models developed to date to simulate long-term outcomes of asthma have been criticized for lacking granularity and ignoring disease heterogeneity. Objective: To propose an alternative approach to modeling asthma...
2.
Nuwamanya E, Nassiwa S, Kuznik A, Waitt C, Malaba T, Myer L, et al.
Value Health Reg Issues
. 2024 Jun;
44:101017.
PMID: 38905817
Objectives: Dolutegravir (DTG) has proved to be more efficacious, tolerable, and safer than efavirenz (EFV) among mothers living with HIV and their infants in Uganda. This study assessed the cost-effectiveness...
3.
Gu J, Kuznik A, Quon P, Chauhan A, Sravya T, Raal F
Eur J Prev Cardiol
. 2023 Jun;
30(17):1874-1880.
PMID: 37314419
Aims: Despite intensive lipid-lowering therapies (LLTs), most patients with homozygous familial hypercholesterolaemia (HoFH) do not achieve guideline recommended low-density lipoprotein cholesterol (LDL-C) targets and are at increased risk of premature...
4.
Feliciano J, McLoone D, Xu Y, Quek R, Kuznik A, Pouliot J, et al.
Front Oncol
. 2023 Apr;
12:1081729.
PMID: 37082098
Objectives: In randomized-controlled crossover design trials, overall survival (OS) treatment effect estimates are often confounded by the control group benefiting from treatment received post-progression. We estimated the adjusted OS treatment...
5.
Kamal M, Kuznik A, Qi L, Wiecek W, Hussein M, Hassan H, et al.
Clin Pharmacol Ther
. 2022 Aug;
112(6):1224-1235.
PMID: 35984050
To assess the combined role of anti-viral monoclonal antibodies (mAbs) and vaccines in reducing severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) transmission and mortality in the United States, an agent-based model...
6.
Freemantle N, Xu Y, Wilson F, Guyot P, Chen C, Keeping S, et al.
Ther Adv Med Oncol
. 2022 Jun;
14:17588359221105024.
PMID: 35747163
Background: For patients with advanced non-small-cell lung cancer (NSCLC) and high (⩾50%) programmed cell death-ligand 1 (PD-L1) expression, effective first-line immune-oncology monotherapies with significant survival benefits are approved, cemiplimab being...
7.
Jovanoski N, Kuznik A, Becker U, Hussein M, Briggs A
J Manag Care Spec Pharm
. 2022 Mar;
28(5):555-565.
PMID: 35238626
Most patients infected with SARS-CoV-2, resulting in COVID-19, have only mild symptoms that can be managed in an ambulatory setting. However, a significant number of patients develop a more severe...
8.
Kuznik A, Smare C, Chen C, Venkatachalam M, Keeping S, Atsou K, et al.
Value Health
. 2022 Jan;
25(2):203-214.
PMID: 35094793
Objectives: This study aimed to evaluate the cost-effectiveness, from a US commercial payer perspective, of cemiplimab versus other first-line treatments for advanced non-small cell lung cancer with programmed death-ligand 1...
9.
Paul E, Konidaris G, Cope S, Chen C, Keeping S, Xu Y, et al.
J Manag Care Spec Pharm
. 2021 Aug;
27(11):1513-1525.
PMID: 34351214
Most cutaneous squamous cell carcinomas (CSCCs) can be treated with surgical excision or radiation; however, approximately 1% of patients develop advanced disease. In 2018, the FDA approved cemiplimab-rwlc as the...
10.
Konidaris G, Paul E, Kuznik A, Keeping S, Chen C, Sasane M, et al.
Value Health
. 2021 Mar;
24(3):377-387.
PMID: 33641772
Objectives: To evaluate the cost-effectiveness of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) from a payer perspective in the United States. Methods: A partitioned survival model was...